BGI Co-Win

Aijie Boya is a medical instrument and magnetic solid-phase material company.

LeadBio Tech is a biotechnology company focused on creating bioartificial blood vessel medical devices. The company specializes in tissue engineering and tissue regeneration solutions aimed at replacing and repairing human tissues and organs. LeadBio Tech develops degradable bioartificial blood vessels utilizing innovative skeleton immune wrapping technology. These products are primarily designed for use in arteriovenous graft surgeries, offering advanced artificial vessel solutions to enhance patient care and outcomes.

Burning Point Medical is a pharmaceutical company focused on developing products for hypertensive and spastic pain disorders. The company aims to provide effective treatments for hypertension, chest pain, and spastic pains, allowing healthcare professionals to offer improved therapeutic options to their patients. Through its innovative solutions, Burning Point Medical addresses significant medical needs in pain management and cardiovascular health.

Waker Biology is a developer of a platform designed to evaluate the safety of gene therapy. The company focuses on high-precision CRISPR/Cas9 quantitative off-target analysis, vector copy number assessment, vector quality control, immune repertoire analysis, and efficient sgRNA screening. Waker Biology provides a comprehensive suite of personalized services that includes sample acceptance and report submission, catering to the diverse needs of its clients in the field of gene therapy safety evaluation.

Yingshu Life is a producer and supplier of medical endoscope systems and devices. They offer solutions for general surgery, urology, gynecology, gastroenterology and pulmonology with a portfolio including rigid endoscope systems, single-use flexible endoscopes, and endoscopic accessories.

Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization.

Hemu Gene is a biotechnology company specializing in gene therapy technology aimed at treating hemoglobin diseases. It possesses independent research and development capabilities and a robust quality management system. The company utilizes two primary gene editing platforms, lentivirus and CRISPR/Cas, to advance its studies on gene therapy vectors and genetic engineering technology. Additionally, Hemu Gene has established hematopoietic stem gene therapy production lines and is actively pursuing international clinical collaborations and registration efforts. Its focus extends to the research and development of cell technology, medical research, and human genetic diagnosis and treatment, enhancing the understanding and application of human gene technology.

YZY Bio is a biotechnology company focused on developing bispecific antibody-based therapies aimed at treating cancer and related complications, as well as age-related ophthalmologic diseases. By leveraging advancements in molecular biology, YZY Bio aims to provide more effective treatment options for patients facing significant medical challenges. The company is dedicated to discovering, developing, and commercializing a new class of anti-tumor bispecific antibodies. Operating primarily in China, YZY Bio generates most of its revenue from this market, addressing critical healthcare needs in oncology and aging-related conditions.

Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines.

OkayBio is a biotechnology company focusing on the research and development of In vitro diagnostic products. OkayBio's products are IVD markers involved in multiple fields, such as infection, cardiovascular disease, renal function, and oncology.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

ToloBio develops molecular diagnostics solutions for pathogen detection, disease screening, and precision medicine.

Targene Medical concentrates on the study, creation, and distribution of tools for accurate and early cancer diagnosis. It is dedicated to entire cancer diagnostic and treatment process. It provides research and development of early detection tools for one type of cancer, multiple types of cancer, and even all cancers.

F&S Pharmatech is a pharmaceutical technology company based in Nanjing, China. The company specializes in the development of differentiated generic drugs and pharmaceutical intermediates, focusing on advanced pharmaceutical chemicals. Its product offerings include key intermediates such as sacubitril and diphenyl piperidine methanol, aimed at supporting research and development centers as well as generic drug developers. F&S Pharmatech also provides contract manufacturing organization (CMO) services and offers intellectual property solutions alongside environmentally friendly chemical technologies. By prioritizing innovation and efficiency, the company seeks to shorten development cycles and reduce costs for customers in the healthcare industry.

Cellnuo develops pharmaceutical products to help patients reduce the incidence of hypoglycemia and maintain healthier blood glucose levels, improving health outcomes for patients.

Ascentawits Pharmaceuticals Ltd. is a biotechnology company established in 2014 and located in Shenzhen, China. The company specializes in the development of anti-tumor drugs, focusing on small molecule targeted conjugated therapies. Ascentawits employs innovative drug designs and screening methods that leverage specific tumor micro-environments to create effective treatments for cancer patients. Through its research and development efforts, the firm aims to provide advanced therapeutic options that address the needs of those affected by cancer.